Uncategorized

Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmer’s Trabecular Metal(TM) Technology

WARSAW, Ind., Feb. 25 /PRNewswire-FirstCall/ — Zimmer Holdings, Inc. (NYSE: ZMH – News; SWX: ZMH – News), a leader in the orthopaedic industry, today announced that data from an independent 10-year Trabecular Metal(TM) Technology comparative clinical study demonstrates the osteoconductive properties of Zimmer’s Trabecular Metal Technology. The study found bone-to-implant gap-filling and positive clinical outcomes up to 10 years after total hip arthroplasty (THA) using products made with Zimmer’s Trabecular Metal Technology.

“This study reaffirms the positive clinical outcomes associated with using Trabecular Metal technology,” commented Cheryl Blanchard, PhD, Zimmer’s Senior Vice President, Research and Development, and Chief Scientific Officer. “Unique to Zimmer, Trabecular Metal technology allows for highly porous metal implants with flexibility very similar to cancellous bone.”

The study, to be published in the Journal of Arthroplasty, followed 143 patients for up to 10 years post-THA. Findings indicate that Trabecular Metal monoblock implants result in a marked reduction in metallic and polyethylene debris and maximize the area available for bone in-growth. Further, the researchers observed a zero revision rate for aseptic loosening throughout the duration of the study and no incidence of implant migration and no radiographic evidence of gross polyethylene wear as measured digitally with (EBRA) Ein-Bild-Rontgen-Analyse.

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button